Rapacuronium bromide: A review of its use in anaesthetic practice

Drugs

Volumn 58, Issue 5, 1999, Pages 887-918

  Onrust, Susan V ^a   Foster, Rachel H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MIVACURIUM; NEOSTIGMINE; RAPACURONIUM BROMIDE; ROCURONIUM; SUXAMETHONIUM; VECURONIUM;

ARTICLE; BOLUS INJECTION; BRONCHOSPASM; CESAREAN SECTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; ELECTIVE SURGERY; ENDOTRACHEAL INTUBATION; FEVER; GENERAL ANESTHESIA; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LIVER DISEASE; NAUSEA; NEUROMUSCULAR BLOCKING; OBESITY; RASH; TACHYCARDIA; VOMITING;

ANIMALS; CLINICAL TRIALS; HUMANS; INTUBATION, INTRATRACHEAL; NEUROMUSCULAR NONDEPOLARIZING AGENTS; VECURONIUM BROMIDE;

EID: 0032800033     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958050-00011     Document Type: Article

References (76)

1. Wiklund RA, Rosenbaum SH. Anesthesiology: First of two parts. N Engl J Med 1997 Oct 16; 337: 1132-41
2. Scott JM, Hunter JM. Use of the new neuromuscular blocking drugs in critically ill patients. Br J Intens Care 1996; 6 (5): 163-4, 166-8
3. Goulden MR, Hunter JM. Rapacuronium (Org 9487): do we have a replacement for succinylcholine? [editorial I]. Br J Anaesth 1999 Apr; 82 (4): 489-91
4. Booij LHDJ. Neuromuscular transmission and its pharmacological blockade Part 1: Neuromuscular transmission and general aspects of its blockade. Pharm World Sci 1997 Feb; 19: 1-12
5. Fisher DM. Clinical pharmacology of neuromuscular blocking. Am J Health System Pharm 1998; 56 Suppl. 1: S1-S13
6. Sparr HJ. Rapid-sequence intubation with non-depolarizing muscle relaxants. Acta Anaesthesiol Scand 1997; 41 Suppl. 111: 111-3
7. Bevan DR. Neuromuscular blocking drugs: Onset and intubation. J Clin Anesth 1997; 9 (6) Suppl.: 36S-9S
8. Savarese JJ. Some considerations on the new muscle relaxants. Anesth Analg 1998 Mar; 86 Suppl.: 119-27
9. Savarese JJ, Kitz RJ. The quest for a short-acting nondepolarizing neuromuscular blocking agent. Acta Anaesthesiol Scand 1973 Suppl. 53: 43-58
10. Bedford RF. From the FDA [letter]. Anesthesiology 1995 Jan; 82 (1): 33A
11. Booij LHDJ. Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation. Pharm World Sci 1997 Feb; 19: 35-44
12. Fu W, Klein KW, Sun R, et al. Effect of neostigmine on reversal of residual neuromuscular blockade after an infusion of ORG 9487 [abstract]. Anesth Analg 1998 Feb; 86 Suppl.: S445
13. Dempsey GA, Dods IM, Hunter JM. Pharmacodynamics of Org 9487 after a bolus dose followed by a continuous infusion in healthy patients [abstract no. 491. Eur J Anaesthesiol 1997 Sep; 14 Suppl. 16: 30
14. van den Brock L, Wierda JM, Smeulers NJ, et al. Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. Br J Anaesth 1994 Sep; 73: 331-5
15. Wierda JMKH, Beaufort AM, Kleef UW, et al. Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents. Org 9453, Org 9489 and Org 9487. Can J Anaesth 1994 Mar; 41: 213-20
16. Wierda JMKH, van den Brock L, Proost JH, et al. Time course of action and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant; a comparison with succinylcholine. Anesth Analg 1993 Sep; 77: 579-84
17. Reynolds LM, Infosino A, Brown R, et al. Intramuscular rapacuronium in infants and children. Anesthesiology 1999 Nov; 91 (5): 1-12
18. Sparr HJ, Mellinghoff H, Blobner M, et al. Comparison of intubating conditions after rapacuronium (Org 9487) and succinylcholine following rapid sequence induction in adult patients. Br J Anaesth 1999 Apr; 82: 537-41
19. Ahboud TK, Bikhazi G, Mroz L, et al. ORG 9487 vs succinylcholine in rapid sequence induction for cesarean section patients: Maternal and neonatal effects [abstract]. Anesthesiology 1997 Sep; 87 Suppl.: A906
20. Motsch J, Meakin G, Meretoja OA, et al. A dose-ranging study of ORG 9487 on endotracheal intubating conditions in infants and children [abstract]. Anesthesiology 1996 Sep; 85 Suppl.: 1084
21. Viby-Mogensen J, Engbaek J, Eriksson LI, et al. Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scandinavica 1996; 40: 59-74
22. Wierda JMKH, Proost JH. Structure-pharmacodynamic-pharmacokinetic relationships of steroidal neuromuscular blocking agents. Eur J Anaesthesiol, Supplement 1995; 12 (11): 45-54
23. Schiere S, Proost JH, Wierda JMKH. Pharmacokinetics and pharmacokinetic/-dynamic (PK/PD) relationship of ORG 9488, the 3-desacetyl metabolite of ORG 9487 [abstract no. A377]. Anesthesiology 1997, 87 (3A)
24. Meretoja OA, Taivainen T, Jalkanen L, et al. A fast-onset short-acting non-depolarizing neuromuscular blocker, ORG 9487, in infants and children [abstract]. Br J Anaesth 1996 Jun; 76 Suppl. 2: 95
25. Schiere S, van den Broek L. Proost JH, et al. Comparison of vecuronium with ORG 9487 and their interaction. Can J Anaesth 1997 Nov; 44: 1138-43
26. Schiere S, Proost JH, Schuringa M, et al. Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). Anesth Analg 1999; 88: 640-7
27. Curran MJ, Donati F, Bevan DR. Onset and recovery of atracurium and suxamethonium-indnced neuromuscular blockade with simultaneous train-of-four anti-single twitch stimulation. Br J Anaesth 1987; 59: 989-94
28. Meistelman C. Effects on laryngeal muscles and intubating conditions with new generation muscle relaxants. Acta Anaesthesiol Belg 1997; 48: 11-4
29. Wright PMC, Brown R, Lau M, et al. A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. Anesthesiology 1999 Jan; 90: 16-23
30. Debaene B, Lieutaud T, Billard V, et al. ORG 9487 neuromuscular block at the adductor pollicis and the laryngeal adductor muscles in humans. Anesthesiology 1997 Jun; 86: 1300-5
31. Organon Teknika. Data on file. 1999
32. Kahwaji R, Bevan DR, Bikhazi G, et al. Dose-ranging study in younger adult and elderly patients of ORG 9487, a new, rapid onset, short-duration muscle relaxant. Anesth Analg 1997 May; 84; 1011-8
33. Lichtor JL, Korttila K, Lane B, et al. Onset time, peak effect, and cardiovascular effects in adult patients after three different doses of ORG 9487 [abstract]. Anesthesiology 1996 Sep; 85 Suppl.: 805
34. Witkowski T, Bartkowski R, Huffnagle S. Onset and recovery of rapacuronium: A comparison with rocuronium [abstract]. Anesthesiology 1998; 89 (3A): A978
35. Miguel R, Bartkowski R, Foldes FF, et al. Comparison of the neuromuscular effects of ORG 9487, mivacurium and succinylcholine [abstract]. Anesth Analg 1998 Feb; 86 Suppl.: 482
36. Bowman WC, Rodger IW, Houston J, et al. Structure: Action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 1988; 69: 57-62
37. Kopman AF. Pancuronium, gallamine and d-tubocurarine compared: Is speed of onset inversely related to drug potency? Anesthesiology 1989; 70: 915-20
38. Scheller MS, Zornow MH, Saidman LJ. Tracheal intubation without the use of muscle relaxants: A technique using propofol and varying doses of alfentanil. Anesth Analg 1992; 75: 788-93
39. Mahajan RP. Is suxamethonium now obsolete? Curr Anaesth Crit Care 1996; 7 (6): 289-94
40. Connolly FM, Mirakhur RK, Loan PB, et al. Time course of action of Org 9487 with or without reversal: Comparison with suxamethonium [abstract]. Br J Anaesth 1995 Apr; 74: 473P
41. Purdy R, Bevan DR, Donati F, et al. Early reversal of rapacuronium with neostigmine. Anesthesiology 1999 Jul; 91 (1); 51-7
42. Hayes A, Reid J, Bresline D, et al. Comparison of recovery following suxamethonium anti Org 9487 (rapacuronium) with and without ncostigmine [abstract no. A.416]. Br J Anaesth 1999 Jun; 82 Suppl. 1: 125-6
43. Bevan DR. Monitoring and reversal of neuromuscular block. Am J Health System Pharm 1998; 56 Suppl. 1: 51-9
44. Szcnohradszky J, Caldwell JE, Wright PCM, et al. Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide. Anesthesiology 1999 Jan; 90: 24-35
45. Duvaldestin P, Slavov V, Rimaniol J-M. ORG 9487 pharmacodynamics in patients with cirrhosis [abstract]. Anesthesiology 1997 Sep; 87 Suppl.: A864
46. Kaplan RF, Fletcher JE, Hannallah R, et al. The ED50 of ORG 9487 in infants and children [abstract]. Anesthesiology 1996 Sep; 85 Suppl.: 1059
47. Kaplan RF, Hannallah R. Darrow E, et al. Potency of ORG 9487 in neonates [abstract]. Anesth Analg 1997 Feb; 84 Suppl.: S437
48. Brandom BW, Bikhazi G, Ginsberg B, et al. Org 9487 in neonates and infants anaesthelized with nitrous oxide-halothane [abstract no.56]. Eur J Anaesthesiol 1997; 14 Suppl. 16: 33-4
49. Kenaan CA, Brandom BW, Bikhazi GB, et al. Neuromuscular effects of ORG9487 compared with 0.2 mg/kg of mivacurium in pediatric patients anesthetized with halothane [abstract]. Anesthesiology 1997 Sep; 87 Suppl.: A 1047
50. Mills KG, Scott JM, Parker CJR, et al. Reversal of single and incremental doses of Org 9487 [abstract no. 50]. Eur J Anaesthesiol 1997 Sep; 14 Suppl. 16: 30-1
51. Danjoux GR, Mills K, Hunter JM, et al. Can antagonism of rapacuronium speed its offset sufficiently to emulate suxamethonium: Neostigmine or edrophonium? [abstract]. Anaesth Intensive Care 1999 Feb; 27: 78-9
52. McCourt KC, Mirakhur RK, Lowry DW, et al. Spontaneous or ncostigmine-induced recovery after maintenance of neuromuscular block with Org 9487 (rapacuronium) or rocuronium following an initial dose of Org 9487. Br J Anaesth 1999 May; 82: 755-6
53. Osmer C, Wulf K, Vögele C, et al. Cardiovascular effects of Org 9487 under isoflurane anaesthesia in man. Eur J Anaesthesiol 1998 Sep; 15: 585-9
54. Witkowski TA, Bartkowski RR. Huffnagle S, et al. Hemodynamic effects of bolus injection of ORG 9487: A comparison with mivacurium and succinylcholine [abstract]. Anesthesiology 1957 Sep; 87 Suppl.: A865
55. Levy JH, Pitts M, Thanopoulos A, et al. The effects of rapacuronium on histamine release and hemodynamics in adult patients undergoing general anesthesia. Anesth Analg 1999; 89: 290-5
56. Bikhazi GB, Deepika KD, Fonseca J, et. al. Cardiovascular effects of ORG 9487 under nitrous oxide harbiturate, fentanyl anesthesia [abstract]. Anesth Analg 1996 Feb; 82 Suppl.: S29
57. Miguel R. Bartkowski R, Foldes FF, et al. The effect of two doses of ORG9487, succinylcholine and mivacurium on heart rate and blood pressure [abstract]. Anesthesiology 1997 Sep; 87 Suppl.: A847
58. Whitford AM, Godschalkx A, Robertson EN, et al. A clinical comparison of some cardiovascular and intraocular effects of ORG9487 vecuronium and succinylcholine [abstract]. Anesthesiology 1997 Sep; 87 Suppl.: A848
59. Muir AW, Sleigh T, Marshall RJ, et al. Neuromuscular blocking and cardiovascular effects of Org 9487, a new short-acting aminosteroidal blocking agent, in anaesthetized animals and in isolated muscle preparations. Eur J Anaesthesiol 1998 Jul; 15: 467-79
60. Yamaguchi K, Huraux C, Szlam F, et al. Vascular effects of ORG9487 in human mammary arteries, a new short acting muscle relaxant [abstract]. Anesth Analg 1998 Apr; 80: SCA 109
61. Fisher DM, Kahwaji R, Bevan D, et al. Factors affectingg the pharmacokinetic characteristics of rapacuronium. Anesthesiology 1999 Apr; 90: 993-1000
62. Lemmens HJM, Drover DR, White PF, et al. The population pharmacokinetics of rapacuronium [abstract]. Clin Pharmacol Ther 1999 Feb; 65: 178
63. Donati F, Varin F, Ducharme J. et al. Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples. Clin Pharmacol Ther 1991; 49: 515-22
64. Atherton DPL, Hunter JM. Clinical Pharmacokinetics of the newer neuromuscular blocking drugs. Clin Pharmacokinet 1999 Mar; 36: 169-89
65. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-turbocurarine. Clin Pharmacol Ther 1979 Mar; 25 (3): 358-71
66. Plaud B, Proost JH, Wierda JMKH, et al. Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. Clin Pharmacol Ther 1995; 58 (2): 185-91
67. Fisher DM, Wright PMC. Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants? Anesthesiology 1997; 86: 567-75
68. Proost JH, Roggeveld J, Wierda JMKH. et al. Relationship between chemical structure and physicochemical properties of series of bulky organic cations and their hepatic uptake and biliary excretion rates. J Pharmacol Exp Ther 1997; 282 (2): 115-26
69. Szcnohradszky J, Caldwell JE, Sharma ML, et al. Interaction of rocuronium (ORG 9426) and phenytoin in a patient undergoing cadaver renal transplantation: A possible pharmacokinetic mechanism? Anesthesiology 1994; 80: 1167-70
70. Meistelman C, Rowan C, Lacroix O, et al. Comparison or intubating conditions after administration of Org 9487 and succinylcholine [abstract]. Br J Anaesth 1999 Jun; 82 Suppl. 1: 147
71. Goldberg ME, Lurijani GE, Azad SS, et al. Comparison of tracheal intubating conditions and neuromuscular blocking profiles after intubating doses of mivacurium chloride or succinylcholine in surgical outpatients. Anesth Analg 1989; 69: 93-9
72. Organon Inc. Org 9487 fur Injection: Integrated Summary of Safety Information. Data on file, 1997 Oct
73. Naguib M, Samarkandi AH, Bakhamees HS, et al. Histaminerelease haemodynamic changes produced by rocuronium, vecuronium, mivacurium, alracurium and tubocurarine. Br J Anaesth 1995; 75: 588-92
74. Organon Inc. Raplon™ (rapacuronium bromide) prescribing information. West Orange, New Jersey, USA, 1999
75. Øberg B, Poulsen TD. Obesity: An anaesthetic challenge. Acta Anaesthesiol Scand 1996; 40: 191-200
76. Bartkowski RR. Recent advances in neuromuscular blocking agents. Am J Health System Pharm 1999 Jun 1; 56 Suppl. 1: S14-17